• Citing Article List

    The journal uses Crossref Cited-by service counts times cited of published articles. Cited-by allows Crossref members to find out who is citing their content. This is the Citing Article List of “Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?”.
    No. Publication Date Citing Article
    1 2022 Marilia Barreca, Noémie Lang, Chiara Tarantelli, Filippo Spriano, Paola Barraja, Francesco Bertoni. Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences, Exploration of Targeted Anti-tumor Therapy. 2022; 763.  https://doi.org/10.37349/etat.2022.00112
    2 2022 Antonio Giovanni Solimando, Eleonora Malerba, Patrizia Leone, Marcella Prete, Carolina Terragna, Michele Cavo, Vito Racanelli. Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche, Frontiers in Oncology. 2022; 12: 973836.  https://doi.org/10.3389/fonc.2022.973836
    3 2023 Clifton C. Mo, Andrew J. Yee, Shonali Midha, Monique A. Hartley‐Brown, Omar Nadeem, Elizabeth K. O'Donnell, Giada Bianchi, Adam S. Sperling, Jacob P. Laubach, Paul G. Richardson. Selinexor: Targeting a novel pathway in multiple myeloma, eJHaem. 2023; 4: 792.  https://doi.org/10.1002/jha2.709
    4 2024 Karen Toledo-Stuardo, Carolina H. Ribeiro, Fabiola González-Herrera, Douglas J. Matthies, María Soledad Le Roy, Claudio Dietz-Vargas, Yesenia Latorre, Ivo Campos, Yuneisy Guerra, Samantha Tello, Valeria Vásquez-Sáez, Pedro Novoa, Nicolás Fehring, Mauricio González, Jose Rodríguez-Siza, Gonzalo Vásquez, Pamela Méndez, Claudia Altamirano, María Carmen Molina. Therapeutic antibodies in oncology: an immunopharmacological overview, Cancer Immunology, Immunotherapy. 2024; 73: 242.  https://doi.org/10.1007/s00262-024-03814-2